Top 100 medical and healthcare startups in UK

Updated: March 04, 2024

1
Funding: £1.1B
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
2
Funding: $1.2B
babylon was founded with a single purpose: To put an accessible and affordable health service in the hands of every person on earth. How? We’ll do this by combining the ever growing computing power of machines, with the best medical expertise of humans to create a comprehensive, immediate and personalized health service and making it universally available.
3
Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
4
Funding: $1.1B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
5
Funding: $808.8M
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
6
Funding: $781.6M
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
7
Funding: $542.9M
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
8
Funding: $540M
Myovant Sciences is to deliver innovative women's health (endometriosis treatment) and prostate cancer solutions by efficiently advancing new medicines to market.
9
Funding: $474.4M
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
10
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Ad
 Advertise your startup
11
Funding: $351.7M
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
12
Funding: $302.1M
Freeline Therapeutics is a biopharmaceutical company specialising in developing liver directed gene therapies for bleeding disorders.
13
Funding: $298.6M
Artios is developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells
14
Funding: $292M
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
15
Funding: $283.3M
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
16
Funding: $271.2M
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
17
Funding: $269.5M
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system
18
Funding: $240.5M
Quell Therapeutics is a cell therapy company
19
Funding: $240M
Barinthus Biotherapeutics is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
20
Funding: $219.2M
Juvenescence AI is focused on developing drugs that were discovered by Artificial Intelligence Techniques.
21
Funding: $217M
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
22
Funding: $217M
Huma combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials
23
Funding: $213M
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
24
Funding: $206.6M
YuLife is a provider of life insurance and policies providing income in the event of critical illness.
25
Funding: $205.5M
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
26
Funding: $191.8M
Kuur Therapeutics is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.
27
Funding: $166.4M
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
28
Funding: £128M
OMass Therapeutics develops new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry.
29
Funding: $159.6M
PepGen is empowering nucleic acid therapeutics to go the distance and building neuromuscular and neurologic pipeline.
30
Funding: $155.2M
Cambridge Epigenetix develops ground-breaking epigenetics tools for DNA methylation (5mC) and hydroxymethylation (5hmC) analysis.
31
Funding: $151.9M
Elvie is a British femtech company developing smarter gadgets for women.
32
Funding: $148.2M
Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment
33
Funding: $143.1M
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
34
Funding: $139M
Palta (previously Haxus) is a health & well-being technology company.
35
Funding: $132.9M
A breathalyzer for disease. Owlstone Medical has developed Breath Biopsy technology to identify non-invasive VOC biomarkers in breath.
36
Funding: $132.5M
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
37
Funding: $130M
MiroBio develops novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases. MiroBio's medicines will activate natural mechanisms to regain control of over-active immune responses triggering these diseases.
38
Funding: $127.5M
Oviva is digitising the treatment of type 2 diabetes and obesity through our unique behaviour change platform.
39
Funding: $121M
reViral is a biotechnology company that develops drugs to treat Respiratory Syncytial Virus (RSV) infection.
40
Funding: $118M
Proximie is a secure software solution that expands virtual surgical collaboration enabling surgeons to share expertise through AR.
41
Funding: $106.7M
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
42
A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
43
Funding: $93M
Causaly develops a biomedical research discovery tool designed to find and unlock key hidden evidence in biomedicine.
44
Funding: $91.1M
Touch Surgery is an interactive mobile surgical simulator that guides you step-by-step through every part of an operation, and every decision that’s made along the way.
45
Funding: $89.5M
Minatx is a therapeutics company uses gene activation mechanisms to discover new medical treatments.
46
Funding: $88.4M
Lumeon is a digital health company that provides care pathway management solutions to the healthcare industry.
47
Funding: £62M
Microbiotica's goal is to create the world’s leading company focused on microbiome biology and its use in medicine
48
Funding: $82.7M
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
49
Funding: $81M
Synthace provides R&D cloud platform which supports scientists to share and access progress with the development of biopharmaceutical therapeutics
50
Funding: $77.9M
Transforming mental healthcare, by unlocking the power of clinical data